MEDIFAST INC
$ 10.63
5.67%
13 Apr - close price
- Market Cap 117,267,000 USD
- Current Price $ 10.63
- High / Low $ 10.64 / 9.99
- Stock P/E N/A
- Book Value 19.29
- EPS -1.70
- Next Earning Report 2026-04-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.09 %
- 52 Week High 15.46
- 52 Week Low 9.22
About
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Analyst Target Price
$12.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-03 | 2025-08-04 | 2025-04-28 | 2025-02-18 | 2024-11-04 | 2024-08-05 | 2024-04-29 | 2024-02-20 | 2023-11-06 | 2023-08-07 | 2023-05-01 |
| Reported EPS | -1.65 | -0.21 | 0.22 | -0.07 | 0.1 | 0.35 | 0.92 | 0.66 | 0.55 | 2.12 | 2.77 | 3.67 |
| Estimated EPS | -0.45 | -0.3 | -0.22 | 0.78 | 0.2424 | -0.28 | 0.39 | 0.78 | 0.96 | 1.07 | 1.44 | 2.4 |
| Surprise | -1.2 | 0.09 | 0.44 | -0.85 | -0.1424 | 0.63 | 0.53 | -0.12 | -0.41 | 1.05 | 1.33 | 1.27 |
| Surprise Percentage | -266.6667% | 30% | 200% | -108.9744% | -58.7459% | 225% | 135.8974% | -15.3846% | -42.7083% | 98.1308% | 92.3611% | 52.9167% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-27 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.55 |
| Currency | USD |
Previous Dividend Records
| Nov 2023 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2023-11-07 | None | None | None | None | None | None | None | None | None |
| Amount | $1.65 | $1.65 | $1.65 | $1.64 | $1.64 | $1.64 | $1.64 | $1.42 | $1.42 | $1.42 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MED
2026-04-12 18:39:16
A Medifast-commissioned survey revealed that a majority of U.S. adults trying to lose weight believe lifestyle changes are essential, even when using weight loss medications. Key findings indicate that 65% think medications are more effective with lifestyle changes, and 73% would still commit to healthy eating, 72% to exercise, and 55% to quality sleep. Medifast emphasizes its holistic OPTAVIA® solution, which combines habit-based programs, coach guidance, and support for those incorporating GLP-1 medications.
2026-04-11 08:24:00
This article analyzes Medifast Inc (MED) and its impact on rotational strategy timing, based on AI models. It highlights stable neutral readings in shorter horizons potentially easing a long-term weak bias, an exceptional short setup with a 41.0:1 risk-reward ratio, and neutral sentiment. The article also outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
2026-04-08 16:11:06
This Yahoo Finance page provides a comprehensive overview of Medifast, Inc. (MED) stock, including its current price, historical data, financial performance, and analyst insights. The company, a health and wellness provider, offers various weight loss and management products, trading at $10.05 with a -1.57% change as of market open. The page also offers profitability metrics and comparisons with similar companies in the Personal Services industry.
2026-04-07 18:13:45
Medifast (MED) is shifting its business strategy from traditional weight loss to a metabolic health approach, introducing new products designed to optimize metabolic function and reduce visceral fat. This strategic pivot, driven by a significant market opportunity and increasing patient abandonment of GLP-1 medications, is expected to improve profitability by Q4 2026 and continue growing into 2027. Despite a recent decline in stock performance, the company anticipates a return to growth and profitability through its science-driven product pipeline, with analysts recommending alternative stocks like Mama's Creations (MAMA), US Foods Holding Corporation (USFD), and B&G Foods (BGS) for consideration.
2026-04-07 16:11:06
Medifast is shifting its focus from traditional weight loss to a broader metabolic health strategy, targeting a large underserved market. The company is developing a new product line leveraging its metabolic synchronization science, designed to reduce visceral fat and improve body composition, especially for individuals transitioning off GLP-1 treatments. Medifast anticipates profitability improvements starting in Q4 2026, with continued earnings growth thereafter, driven by this science-led product pipeline.
2026-04-07 15:00:00
Medifast (MED) is shifting its business model from traditional weight loss to a comprehensive metabolic health approach, introducing new products based on metabolic science aimed at reducing visceral fat and preserving lean muscle. This strategic shift is driven by the growing market opportunity in metabolic health, particularly among individuals discontinuing GLP-1 medications, with the company anticipating improved profitability by Q4 2026 and sustained growth into 2027.
